Skip to main content
. 2017 Sep;6(5):473–483. doi: 10.21037/acs.2017.08.02

Table 4. Early clinical outcomes.

Variable Total (n=171) CV group (n=87) ES group (n=84) P
In-hospital outcomes
   Stroke, n (%) 3 (1.8) 2 (2.3) 1 (1.2) 1
   Major vascular complication, n (%) 14 (8.2) 5 (5.8) 9 (10.7) 0.24
Bleeding, n (%)
   Major 30 (17.4) 15 (17.2) 15 (17.9) 0.55
   Life-threatening 9 (5.3) 3 (3.5) 6 (7.1)
AKI, n (%)
   Stage 1 11 (6.4) 9 (10.3) 2 (2.4) 0.07
   Stage 2 14 (8.2) 4 (4.6) 10 (11.9)
   Stage 3 11 (6.4) 3 (6.9) 5 (6.0)
   New PPM implantation, n (%) 38 (22.3) 33 (37.9) 5 (5.9) <0.001
Thirty-day outcomes
   All-cause mortality, n (%) 8 (4.7) 5 (5.8) 3 (3.6) 0.72
   Cardiovascular mortality, n (%) 7 (4.1) 4 (4.6) 3 (3.6) 1
   All stroke, n (%) 3 (1.8) 2 (2.3) 1 (1.2) 1
   Myocardial infarction >72 h, n (%) 5 (2.9) 3 (3.5) 2 (2.4) 1
   Congestive heart failure, n (%) 8 (4.7) 6 (6.9) 2 (2.4) 0.28
   Early safety VARC 2, n (%) 130 (76.0) 71 (81.6) 59 (70.2) 0.08
   Combined safety VARC 1, n (%) 140 (81.9) 73 (83.9) 67 (79.8) 0.48
   Major bleeding, n (%) 33 (19.3) 15 (17.2) 18 (21.4) 0.49
   Minor bleeding, n (%) 18 (10.5) 8 (9.2) 10 (11.9) 0.56
   New PPM implantation, n (%) 42 (24.5) 35 (40.2) 7 (8.3) <0.001

Data are expressed as absolute values and percentages. , early safety VARC 2 was a composite of all-cause mortality, all stroke (disabling and non-disabling), life-threatening bleeding, AKI stage 2 or 3 (including renal replacement therapy), coronary artery obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure. , combined safety VARC 1 was a composite of all-cause mortality, major stroke, life-threatening (or disabling) bleeding, AKI stage 3 (including renal replacement therapy), peri-procedural myocardial infarction, major vascular complication, repeat procedure for valve-related dysfunction. AKI, acute kidney injury; PPM, permanent pacemaker.